US/UK/Canada

Share

Contacts

  • Immunovia AB
    Medicon Village Scheelevägen 8 SE-223 63 Lund
    +46 46 275 60 00
    http://www.immunovia.com
    • Pick a time period -
    Tags ( Active)

    Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas—Inherited Gastrointestinal Cancers

    PHILADELPHIA (USA) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company’s next-generation test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC).   The Scientific Committee of the CGA-IGC evaluated and accepted Immunovia’s abstract, which reports outcomes from the company’s model-development study, for presentation at the meeting. Immunovia’s submission was also recognized for inclusion in the Henry Lynch

    Invitation to Immunovia’s Q3 presentation

    LUND (SWEDEN) – Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com   Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.   Telephone numbers and webcast

    Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium

    SAN DIEGO (USA) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration of 51 pancreatic centers worldwide conducting unprecedented research for the early detection of pancreatic cancer in individuals with increased risk for the disease.   Immunovia will share results from studies of its next-generation test to detect stage 1 and 2 pancreatic cancer, including the discovery study, model-development study, and analytical validation. As reported

    Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample collection effort marks a key milestone toward successfully completing the clinical validation study.  The study seeks to confirm the sensitivity and specificity reported previously in the company’s model-development study of its new test. The trial will be a case-control study evaluating the accuracy of the next-generation test

    Immunovia completes analytical validation of its next-generation pancreatic cancer test

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation of its next-generation test designed to detect early-stage pancreatic cancer. The validation demonstrated excellent results across a comprehensive set of parameters, reinforcing the reliability and robustness of the test.  The biomarkers that make up Immunovia’s next-generation test demonstrated excellent performance in a series of experiments. These experiments evaluated over 23 key performance attributes of the next-

    Change in number of shares and votes in Immunovia AB (publ)

    LUND (SWEDEN) – During September 2024, the registered number of shares and votes in Immunovia AB (publ) (“Immunovia”) has increased due to the rights issue of units resolved by the board of directors on 20 May 2024 and approved by the annual general meeting on 19 June 2024, as well as the directed issue of units to underwriters in the rights issue resolved by the board of directors on 12 September 2024, based on the authorization granted by the annual general meeting on 19 June 2024. As of 30 September 2024, the registered number of shares and votes in Immunovia amounts to 169,711,476.

    Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer (abstract #B027).   Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. The company disclosed its method for selecting the biomarkers that comprise the test, the construction of the test algorithm, and the test’s performance and stability. In the study of 623 patient samples,

    Immunovia carries out a directed issue of units to guarantors in connection with the completed rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.   LUND (SWEDEN) – The board of directors of Immunovia AB (publ) (”Immunovia” or ”the Company”), has today, based on the authorization granted by the annual general meeting on 19 June 2024, resolved on a directed issue of

    Immunovia announces final outcome in rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.                                                                                                  LUND (SWEDEN) – The board of directors of Immunovia AB (publ) (“Immunovia” or the “Company”) today announces the final

    Immunovia publishes preliminary outcome in rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.                                                                                                  LUND (SWEDEN) – Immunovia AB (publ) (“Immunovia” or the “Company”) today announces the preliminary outcome of the rights

    Immunovia publishes prospectus in connection with forthcoming rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.                                                                                                  LUND (SWEDEN) – The board of directors of Immunovia AB (publ) ("Immunovia" or the "Company") has prepared a prospectus (

    Immunovia announces final terms of rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.     LUND (SWEDEN) – On 20 May 2024, the board of directors of Immunovia AB (“Immunovia” or the “Company”) resolved on an issue of units, consisting of shares and warrants, with preferential rights for the Company’s

    Immunovia Publishes Interim Report for January-June 2024

    April-June 2024 · Net sales, consisting of royalties, amounted to 85 KSEK (412) · Net earnings amounted to -25.6 MSEK (-185.1), where one-off costs second quarter 2023 of 141 MSEK impact comparability between the years. · Earnings per share before and after dilution were -0.57 SEK (-4.00). · Cash Flow from operating activities amounted to -28.2 MSEK (-43.3). · Cash and equivalents at the end of the period amounted to 36.8 MSEK (143.9). · The successful development of accurate and precise assays to measure targeted proteins for the next-generation test was announced on

    Immunovia’s next generation test to be included in large study of pancreatic cysts funded by the U.S. National Institutes of Health

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company’s next-generation test to detect pancreatic cancer has been selected for inclusion in a US-government-funded study to evaluate biomarker tests for monitoring cystic tumors of the pancreas.   The study’s lead author is Diane M. Simeone, an internationally recognized expert in pancreatic neoplasms and the Director of Moores Cancer Center at University of California San Diego Health.   The study will assess the use of biomarker tests to detect pancreatic

    Immunovia files US patent application to protect its next-generation test

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces the company has filed a US provisional patent application to protect the intellectual property embodied in its next-generation test to detect stage 1 and 2 pancreatic cancer.   The patent application claims methods of diagnosing pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The company is seeking patent protection for the unique combination of five specific biomarkers used in its test, as well as the method for combining these

    Immunovia completes development of its pancreatic cancer detection test after substantially increasing test accuracy

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces enhanced performance for its next-generation test for detecting stage 1 and 2 pancreatic ductal adenocarcinomas (PDAC) in high-risk individuals, which are potentially curable with surgery and modern treatments.   On 22 April 2024 , Immunovia announced positive results from the initial model-development study for its

    Invitation to Immunovia’s Q2 presentation

    LUND (SWEDEN) – Immunovia will publish its second quarter 2024 results on August 5, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com     Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.   Telephone numbers and webcast

    Immunovia presents data from discovery study at 2024 PancreasFest medical conference

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today presented detailed discovery study results for the company’s next-generation early detection test for pancreatic cancer at the PancreasFest 2024 Annual Meeting (abstract #P33).    PancreasFest is an annual conference of physicians and translational researchers with special interest in the pancreas who convene to find new ways to improve the care of patients with pancreatic disease, including pancreatic cancer. It is organized by the Collaborative Alliance for Pancreatic Education and

    Immunovia’s new lab staffed and operational after rapid implementation

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today offers an update on its new lab in Research Triangle Park, USA.    Immunovia announced on 29 April  the company’s plans to streamline its lab operations and move to Research Triangle Park (RTP), following the successful model development study of the next generation test. After taking occupancy on 21 May 2024,

    BULLETIN FROM THE ANNUAL GENERAL MEETING ON 19 JUNE 2024 IN IMMUNOVIA AB (PUBL)

    LUND (SWEDEN) – Today, on 19 June 2024, the annual general meeting of Immunovia AB (publ) was held. A summary of the adopted resolutions follows below.      Resolution on the adoption of the accounts and allocation of result  The annual general meeting resolved to adopt the profit and loss account and balance sheet and the consolidated profit and loss statement and consolidated balance sheet. The annual general meeting also resolved to allocate the company’s result in accordance with the board's proposal, which means that no dividend will be paid, and that available funds of SEK 60,

    NOTICE OF ANNUAL GENERAL MEETING IN IMMUNOVIA AB (PUBL)

    The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.     May 20, 2024, Lund, Sweden   LUND (SWEDEN) - The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Annual General Meeting (“AGM”) to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund on Wednesday 19 June 2024 at 10 a.m. CEST. Right to participate and notice of participation A shareholder who wishes to participate in the AGM must (i) be registered in the share

    Immunovia carries out a rights issue of units of approximately SEK 70 million and raises bridge loans

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.    May 20, 2024, Lund, Sweden LUND (SWEDEN) - The Board of Directors of Immunovia AB (publ) (“Immunovia” or the “Company”) has today, subject to approval by the Annual General Meeting on 19 June 2024, resolved to carry out

    Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.    As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia’s next-generation test. Her primary responsibilities will be staffing, developing, and overseeing the laboratory team; quality assurance and regulatory compliance; and facilitating collaboration and communication with external partners,

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media